Administration of the Synthetic Cannabinoid WIN55,212-2 Increases BDNF Expression Levels in the Adolescent Rat Brain.
Alejandro Guadalupe Torres, Jordan Santos, Dolores Vazquez Sanroman
Cannabis and cannabinoid research February 1, 2026 DOI: 10.1177/25785125251410807 via PubMed
Summary
AI-generated from the abstractChronic administration of the synthetic cannabinoid WIN55,212-2 during adolescence alters levels of brain-derived neurotrophic factor (BDNF) in specific brain regions of male adolescent rats. WIN55,212-2 increased pro-BDNF in the cerebellar vermis and mature BDNF in the medial prefrontal cortex, suggesting potential effects on synaptic plasticity and neurodevelopment. The study used male Sprague-Dawley rats given injections of WIN (0.8 mg/kg) or saline every 48 hours from postnatal day 30 to 37, with tissue collected one hour after the final injection.
Study at a glance
| Characteristics | Controlled experiment Peer reviewed |
|---|---|
| Population | Male adolescent Sprague-Dawley rats |
| Interventions | WIN55 212-2 |
| Dose | 0.8 mg/kg |
| Duration | From postnatal day 30 to 37, tissue collected one hour after final injection |
| Keywords | Bdnf Win55-212-2 Adolescence Cannabinoids Cerebellar vermis |
| Key finding | Chronic WIN55,212-2 administration increased pro-BDNF in the cerebellar vermis and mature BDNF in the medial prefrontal cortex of male adolescent rats. |
Abstract
The increase in cannabinoid use among adolescents has become a public health concern in North America, with more than one-third of 12th graders in the United States reporting consumption of some form of cannabis within the past year (2023).1,2 The use of cannabinoids during adolescence, a vulnerable stage for brain development, may alter the neuroplasticity dependent on brain-derived neurotrophic factor (BDNF),3 an essential protein for brain development. BDNF is found either as its precursor, pro-BDNF, involved in synaptic pruning and apoptosis, or its mature form (m-BDNF), which stimulates dendritic growth and cell survival. The synthetic cannabinoid Win55,212-2 (WIN) acts as a dual agonist for the endocannabinoid CB1 and CB2 receptors (eCBRs), emulating the psychotropic activity of Δ9-tetrahydrocannabinol. This study investigates the impact of WIN administration on levels of pro and m-BDNF in the adolescent brain (medial prefrontal cortex [mPFC], hippocampus, and cerebellar vermis[CbVr]) of adolescent male rats. Male adolescent Sprague-Dawley rats received two intraperitoneal injections, either WIN (0.8 mg/kg) or saline solution (0.9% NaCl) every 48 h, from postnatal day (PND) 30 to 37. On the final day (PND 38), a single injection of either WIN or saline was administered. The rat's whole brain tissue was collected an hour after the last injection. Chronic WIN administration during adolescence caused a significant increase in pro-BDNF levels in the brain's CbVr and m-BDNF in the mPFC. Our findings suggest that chronic WIN administration can alter the baseline levels of pro and m-BDNF in the brains of male adolescent rats, which may have implications for synaptic plasticity and neurodevelopment.